Samuel Y. Ng

Hematology
75 Francis St
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Splitting from a lump: harmonizing ALCL classification.

Splitting from a lump: harmonizing ALCL classification.

Journal: Blood
Published: March 12, 2026

A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphoma.

A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphoma.

Journal: Blood advances
Published: November 24, 2025

A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

Journal: Blood advances
Published: November 24, 2025

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.

Journal: Blood neoplasia
Published: June 12, 2024

A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.

A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.

Journal: Leukemia & lymphoma
Published: March 09, 2024

Abstinence scoring algorithms for treatment of neonatal opioid withdrawal syndrome (NOWS).

Abstinence scoring algorithms for treatment of neonatal opioid withdrawal syndrome (NOWS).

Journal: Journal of perinatology : official journal of the California Perinatal Association
Published: October 24, 2023

TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.

TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.

Journal: Science translational medicine
Published: September 20, 2023

Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.

Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.

Journal: Leukemia & lymphoma
Published: September 14, 2023

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.

Journal: Blood advances
Published: September 01, 2023

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

Journal: Cell reports. Medicine
Published: July 22, 2023

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.

Journal: Annals of hematology
Published: May 16, 2023

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.

Journal: Blood
Published: February 22, 2023
Showing 1-12 of 38

Last Updated: 09/26/2026